HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.1%

Neg 0% Neu 89.1% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.